Page 4 - Translational Pharmacology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Translational pharmacology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Translational Pharmacology Today - Breaking & Trending Today

Sapience Therapeutics Awarded SBIR Phase I Grant from National Institute of Allergy and Infectious Diseases

Sapience Therapeutics Awarded SBIR Phase I Grant from National Institute of Allergy and Infectious Diseases
News provided by
Share this article
Share this article
HARRISON, N.Y., May 18, 2021 /PRNewswire/ Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it was awarded a Small Business Innovative Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to investigate the inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide. The grant will provide funds over two years to support the discovery and development of peptide therapeutics against coronaviruses, including SARS-CoV-2 (COVID-19). ....

Barry Kappel , Amy Conrad , Jim Rotolo , Head Of Research Sapience Therapeutics , National Institutes Of Health , National Institute Of Allergy , Small Business Innovative Research , Sapience Therapeutics Inc , Sapience Therapeutics , National Institute , Infectious Diseases , National Institutes , Translational Pharmacology , Gene Merutka , Chief Executive , Investor Contact , பாரி கப்பல் , ஆமி கான்ராட் , ஜிம் ரோட்டோலோ , தலை ஆஃப் ஆராய்ச்சி சாபின்செ சிகிச்சை , தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் , தேசிய நிறுவனம் ஆஃப் ஒவ்வாமை , சிறிய வணிக புதுமையானது ஆராய்ச்சி , சாபின்செ சிகிச்சை இன்க் , சாபின்செ சிகிச்சை , தேசிய நிறுவனம் ,

Sapience Therapeutics Awarded SBIR Phase I Grant from National Institute of Allergy and Infectious Diseases

Sapience Therapeutics Awarded SBIR Phase I Grant from National Institute of Allergy and Infectious Diseases
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Barry Kappel , Amy Conrad , Jim Rotolo , Head Of Research Sapience Therapeutics , National Institutes Of Health , National Institute Of Allergy , Small Business Innovative Research , Sapience Therapeutics Inc , Sapience Therapeutics , National Institute , Infectious Diseases , National Institutes , Translational Pharmacology , Gene Merutka , Chief Executive , Investor Contact , பாரி கப்பல் , ஆமி கான்ராட் , ஜிம் ரோட்டோலோ , தலை ஆஃப் ஆராய்ச்சி சாபின்செ சிகிச்சை , தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் , தேசிய நிறுவனம் ஆஃப் ஒவ்வாமை , சிறிய வணிக புதுமையானது ஆராய்ச்சி , சாபின்செ சிகிச்சை இன்க் , சாபின்செ சிகிச்சை , தேசிய நிறுவனம் ,

Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conference

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conference
Cue Biopharma, Inc.May 6, 2021 GMT
CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will give a poster presentation at the New York Academy of Sciences 2021 Frontiers in Cancer Immunotherapy meeting, which is being held virtually from May 12-14, 2021. The presentation will highlight clinical and preclinical data supporting the mechanism of action (MOA) for the Immuno-STAT™ ....

United Kingdom , United States , Georgeb Zavoico , Steve Quayle , Darren Opland , Cue Biopharma Inc , Lifesci Communications , Investor Relations Corporate Development , York Academy Of Sciences , New York Academy , Selective Targeting , Targeting Tumor Heterogeneity , Tumor Escape Mechanisms , Vice President , Translational Pharmacology , Virtual Poster Session , Scientific Publications , Investor Relations , Corporate Development , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , ஸ்டீவ் குயில் , முதலீட்டாளர் உறவுகள் பெருநிறுவன வளர்ச்சி , யார்க் கலைக்கழகம் ஆஃப் அறிவியல் , புதியது யார்க் கலைக்கழகம் , துணை ப்ரெஸிடெஂட் ,

Biotechnology Company Centivax Officially Launches

Biotechnology Company Centivax Officially Launches
News provided by
Share this article
Share this article
SAN FRANCISCO, April 29, 2021 /PRNewswire/ Centivax Inc. is proud to announce its launch on Jan. 1, 2021, as a fully independent biotechnology company developing broad-spectrum therapeutics and a vaccines portfolio, including indications in COVID-19, multi-drug resistant bacteria, influenza, antivenom and oncology. Our unusually mature portfolio of fully owned Centivax assets has been made possible by advanced computational immunoengineering technology platforms and intellectual property that enable Centivax to rapidly create the broad-spectrum antibodies and broad-spectrum vaccines clearly needed in 21st-century medicine, says Dr. Jacob Glanville, Founder and CEO of Centivax. It is these platforms that enable Centivax to enter clinical development of our first therapeutic within eight months of launch. ....

Nicholas Bayless , David Gangemi , Pamela Garzone , Jacob Glanville , Sawsan Youssef , David Tsao , Stephanie Wisner , Naval Medical Research Center , Walter Reed Army Institute Of Research , National Institute For Innovation , National Institute Of Health , Melinda Gates Foundation , Lab At University Of Kent , University Of San Francisco Biotechnology , Auburn University , Infectious Diseases Research Program , Kim Lab At Stanford University , Scripps Research Institute , Galveston National Labs , University Of Georgia , University Of San Carlos , Centivax Inc , Regulatory Affairs For Centivax , Technology Enterprise Consortium , Stanford University , Distributed Bio ,